Made up of many countries, each with its own language, in a market that requires a great deal of repackaging, it’s no wonder that E.U. pharma regulations differ substantially from those in the U.S. How each region best protects patient safety is different. How they each verify unique product identifiers is different. And so is the framework each region has developed to introduce new regulations. But there are similarities too, such as the information each unique product identifier must contain.
In a new whitepaper, we look at these differences and similarities, and help members of the global pharma supply chain make sure they’ve got their ducks in a row to comply with both sets of regulations.